$SWKH
SWK Holdings Corp Stock $swkh

$swkh Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155278124000343 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$11.54M	$11.78M
YoY Change	21.52%	25.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.997M	$8.007M
YoY Change	202.25%	215.24%
% of Gross Profit
Research & Development	$520.0K	$530.0K
YoY Change	-65.54%	-26.29%
% of Gross Profit
Depreciation & Amortization	$421.0K	$514.0K
YoY Change	-33.91%	-20.68%
% of Gross Profit
Operating Expenses	$520.0K	$530.0K
YoY Change	-65.54%	-26.29%
Operating Profit
YoY Change
Interest Expense	$1.119M	$1.256M
YoY Change	208.26%	590.11%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$5.430M	$1.090M
YoY Change	0.78%	-75.92%
Income Tax	$1.035M	$229.0K
% Of Pretax Income	19.06%	21.01%
Net Earnings	$4.395M	$861.0K
YoY Change	11.72%	-81.42%
Net Earnings / Revenue	38.08%	7.31%
Basic Earnings Per Share	$0.35	$0.07
Diluted Earnings Per Share	$0.35	$0.07
COMMON SHARES
Basic Shares Outstanding	12.47M shares	12.50M shares
Diluted Shares Outstanding	12.53M shares	12.54M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.549M	$5.498M
YoY Change	-18.46%	69.48%
Cash & Equivalents	$5.549M	$5.498M
Short-Term Investments
Other Short-Term Assets	$1.859M	$2.086M
YoY Change	-1.38%	62.08%
Inventory
Prepaid Expenses
Receivables	$7.384M	$6.352M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.79M	$13.94M
YoY Change	13.17%	57.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.008M	$5.212M
YoY Change	-10.54%	-7.38%
Goodwill
YoY Change
Intangibles	$232.0K	$6.198M
YoY Change	-96.84%	-20.17%
Long-Term Investments	$731.0K	$394.0K
YoY Change	1138.98%	496.97%
Other Assets	$4.504M	$3.888M
YoY Change	44.22%	61.93%
Total Long-Term Assets	$306.6M	$308.4M
YoY Change	10.53%	5.67%
TOTAL ASSETS
Total Short-Term Assets	$14.79M	$13.94M
Total Long-Term Assets	$306.6M	$308.4M
Total Assets	$321.4M	$322.4M
YoY Change	10.65%	7.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.310M	$2.867M
YoY Change	11.6%	59.28%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.526M	$4.376M
YoY Change	84.45%	-64.47%
LONG-TERM LIABILITIES
Long-Term Debt	$31.08M	$30.93M
YoY Change
Other Long-Term Liabilities	$1.566M	$1.859M
YoY Change	-33.7%	-34.47%
Total Long-Term Liabilities	$1.566M	$1.859M
YoY Change	-33.7%	-34.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.526M	$4.376M
Total Long-Term Liabilities	$1.566M	$1.859M
Total Liabilities	$38.17M	$42.06M
YoY Change	130.52%	59.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.140B	-$4.144B
YoY Change	-0.29%	-0.29%
Common Stock	$12.00K	$12.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$283.2M	$280.3M
YoY Change
Total Liabilities & Shareholders Equity	$321.4M	$322.4M
YoY Change	10.65%	7.19%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$4.395M	$861.0K
YoY Change	11.72%	-81.42%
Depreciation, Depletion And Amortization	$421.0K	$514.0K
YoY Change	-33.91%	-20.68%
Cash From Operating Activities	$5.413M	$4.430M
YoY Change	14.59%	567.17%
INVESTING ACTIVITIES
Capital Expenditures	$21.00K
YoY Change	-88.52%
Acquisitions
YoY Change
Other Investing Activities	-$4.347M	$9.181M
YoY Change	-129.03%	-182.91%
Cash From Investing Activities	-$4.368M	$9.181M
YoY Change	-129.53%	-182.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-994.0K	-$13.35M
YoY Change	-93.77%	-277.84%
NET CHANGE
Cash From Operating Activities	5.413M	$4.430M
Cash From Investing Activities	-4.368M	$9.181M
Cash From Financing Activities	-994.0K	-$13.35M
Net Change In Cash	51.00K	$262.0K
YoY Change	-98.57%	-109.0%
FREE CASH FLOW
Cash From Operating Activities	$5.413M	$4.430M
Capital Expenditures	$21.00K
Free Cash Flow	$5.392M	$4.430M
YoY Change	18.74%	575.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses		usd
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2023Q1	swkh	Loss On Exercise Of Warrant LossOnExerciseOfWarrant		usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2023Q1	swkh	Loss On Exercise Of Warrant LossOnExerciseOfWarrant		usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest		usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4376000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3944000	usd
CY2024Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	4900000	usd
CY2023Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	4900000	usd
CY2023Q4	us-gaap	Unsecured Debt UnsecuredDebt	30781000	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	12350000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1859000	usd
CY2024Q1	us-gaap	Unsecured Debt UnsecuredDebt	30927000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1964000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	42062000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	53939000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12481944	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12481944	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12497770	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12497770	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4424216000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4425104000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4143940000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4144801000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	280288000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	280315000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	322350000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	334254000	usd
CY2024Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	11454000	usd
CY2023Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	9260000	usd
CY2024Q1	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	279000	usd
CY2023Q1	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	118000	usd
CY2024Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	46000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	33000	usd
CY2024Q1	us-gaap	Revenues Revenues	11779000	usd
CY2023Q1	us-gaap	Revenues Revenues	9411000	usd
CY2024Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	5323000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1256000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	182000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	530000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	719000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	514000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	648000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2684000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2540000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	-1472000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	-5322000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-95000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-982000	usd
CY2024Q1	swkh	Loss On Exercise Of Warrant LossOnExerciseOfWarrant	-143000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-231000	usd
CY2023Q1	swkh	Derivative Instrument Receivable DerivativeInstrumentReceivable	-388000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	283000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	915000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	311000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1412000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	87000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	186000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1090000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4526000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-109000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	861000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12475000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12540000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12875000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	280315000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	111000	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	999000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	861000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	280288000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	279929000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2023Q1	swkh	Effect Of Adoption Of Accounting Standard EffectOfAdoptionOfAccountingStandard	-9683000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	531000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4635000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	274385000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	861000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2024Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	5323000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	91000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	68000	usd
CY2024Q1	swkh	Noncash Interest Expense NoncashInterestExpense	248000	usd
CY2023Q1	swkh	Noncash Interest Expense NoncashInterestExpense	15000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	229000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-122000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	95000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	982000	usd
CY2024Q1	swkh	Loss On Exercise Of Warrant LossOnExerciseOfWarrant	-143000	usd
CY2024Q1	swkh	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-918000	usd
CY2023Q1	swkh	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	186000	usd
CY2024Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-231000	usd
CY2024Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	1256000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	1466000	usd
CY2024Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	478000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	351000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	111000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	514000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648000	usd
CY2024Q1	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-1623000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-1251000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4430000	usd
CY2024Q1	swkh	Derivative Instrument Receivable DerivativeInstrumentReceivable	831000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	664000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	258000	usd
CY2024Q1	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	446000	usd
CY2023Q1	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	12990000	usd
CY2024Q1	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	9362000	usd
CY2023Q1	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	1906000	usd
CY2024Q1	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	7000	usd
CY2023Q1	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	10000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9181000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11082000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-12350000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	8037000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	999000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	531000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13349000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7506000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	262000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2912000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5236000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6156000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5498000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3244000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13224000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13901000	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	261285000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	274504000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13901000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11846000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	-11786000	usd
CY2024Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	5323000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	6000000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	11846000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13224000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13224000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11786000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zQ7im73tIeo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i><span id="xdx_86A_zXm2JziDrSD3">Use of Estimates</span></i></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; impairment of finance receivables; allowance for credit losses; long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	number
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11786000	usd
CY2024Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	274509000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	861000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12475000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	65000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	42000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12540000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12875000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	163000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	119000	shares
CY2024Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	274509000	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	288405000	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	288405000	usd
CY2024Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13224000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13901000	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	261285000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	274504000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear	62836000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	74662000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	43703000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	27980000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	34342000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	30986000	usd
CY2024Q1	us-gaap	Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss	274509000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear	77925000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	63420000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	49416000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	28295000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	37503000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	31846000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss	288405000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23652000	usd
CY2024Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	6198000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23363000	usd
CY2023Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	6487000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	866000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1154000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1154000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1154000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1037000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	833000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6198000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	45000000.0	usd
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	60000000.0	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	32969000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	32969000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2042000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2188000	usd
CY2024Q1	us-gaap	Unsecured Debt UnsecuredDebt	30927000	usd
CY2023Q4	us-gaap	Unsecured Debt UnsecuredDebt	30781000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	32969000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	32969000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	125000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	98000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	15000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	140000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	99000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	384000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	504000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	461000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	465000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	405000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	272000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2491000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	1509000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	9000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1509000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	number
CY2024Q1	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	11733000	usd
CY2024Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	46000	usd
CY2024Q1	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	5323000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1256000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	530000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	514000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2684000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-382000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	861000	usd
CY2023Q1	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	9378000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	33000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	182000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	719000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	648000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2540000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-796000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-109000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001552781-24-000343-index-headers.html	Edgar Link	pending
0001552781-24-000343-index.html	Edgar Link	pending
0001552781-24-000343.txt	Edgar Link	pending
0001552781-24-000343-xbrl.zip	Edgar Link	pending
e24218001.jpg	Edgar Link	pending
e24218_ex10-2.htm	Edgar Link	pending
e24218_ex31-1.htm	Edgar Link	pending
e24218_ex32-1.htm	Edgar Link	pending
e24218_swkh-10q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
e24218_swkh-10q_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swkh-20240331.xsd	Edgar Link	pending
swkh-20240331_cal.xml	Edgar Link	unprocessable
swkh-20240331_def.xml	Edgar Link	unprocessable
swkh-20240331_lab.xml	Edgar Link	unprocessable
swkh-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWKH
SWK Holdings Corp Stock $swkh

2024 Q2 Form 10-Q Financial Statement

#000155278124000343 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH SWK Holdings Corp Stock $swkh

2024 Q2 Form 10-Q Financial Statement

#000155278124000343 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH
SWK Holdings Corp Stock $swkh